全文获取类型
收费全文 | 2527367篇 |
免费 | 209990篇 |
国内免费 | 4765篇 |
专业分类
耳鼻咽喉 | 35976篇 |
儿科学 | 76873篇 |
妇产科学 | 66343篇 |
基础医学 | 354821篇 |
口腔科学 | 71187篇 |
临床医学 | 230991篇 |
内科学 | 500506篇 |
皮肤病学 | 50050篇 |
神经病学 | 216047篇 |
特种医学 | 100963篇 |
外国民族医学 | 899篇 |
外科学 | 384299篇 |
综合类 | 58987篇 |
现状与发展 | 3篇 |
一般理论 | 1235篇 |
预防医学 | 206174篇 |
眼科学 | 58847篇 |
药学 | 188267篇 |
5篇 | |
中国医学 | 4636篇 |
肿瘤学 | 135013篇 |
出版年
2018年 | 27086篇 |
2017年 | 21118篇 |
2016年 | 23072篇 |
2015年 | 26229篇 |
2014年 | 37850篇 |
2013年 | 57505篇 |
2012年 | 78179篇 |
2011年 | 82554篇 |
2010年 | 48399篇 |
2009年 | 46268篇 |
2008年 | 78776篇 |
2007年 | 83703篇 |
2006年 | 84159篇 |
2005年 | 82655篇 |
2004年 | 79528篇 |
2003年 | 76720篇 |
2002年 | 75537篇 |
2001年 | 113892篇 |
2000年 | 117636篇 |
1999年 | 99868篇 |
1998年 | 29947篇 |
1997年 | 27344篇 |
1996年 | 27121篇 |
1995年 | 26114篇 |
1994年 | 24518篇 |
1993年 | 22831篇 |
1992年 | 80315篇 |
1991年 | 77258篇 |
1990年 | 74392篇 |
1989年 | 71579篇 |
1988年 | 66648篇 |
1987年 | 65609篇 |
1986年 | 62116篇 |
1985年 | 59272篇 |
1984年 | 45378篇 |
1983年 | 38807篇 |
1982年 | 24290篇 |
1981年 | 21602篇 |
1980年 | 20247篇 |
1979年 | 41947篇 |
1978年 | 29744篇 |
1977年 | 25090篇 |
1976年 | 23483篇 |
1975年 | 24531篇 |
1974年 | 30176篇 |
1973年 | 28509篇 |
1972年 | 26590篇 |
1971年 | 24438篇 |
1970年 | 23027篇 |
1969年 | 21289篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
151.
152.
153.
William G. Breen Krishan R. Jethwa Nathan Y. Yu Grant M. Spears William S. Harmsen Robert C. Miller Jonathan B. Ashman William G. Rule Terence T. Sio Michelle A. Neben-Wittich Michael G. Haddock Amit Mahipal Mark J. Truty Christopher L. Hallemeier Kenneth W. Merrell 《Practical radiation oncology》2021,11(1):e63-e69
PurposeOur purpose was to determine the effect of chemoradiotherapy (CRT) on patient-reported quality of life (QOL) for patients with intact pancreas cancer.Methods and MaterialsWe reviewed a prospective QOL registry for patients with intact, clinically localized pancreatic ductal adenocarcinoma treated with CRT between June 2015 and November 2018. QOL was assessed pre-CRT (immediately before CRT, after neoadjuvant chemotherapy) and at the completion of CRT with the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) and its component parts: FACT-General (FACT-G) and hepatobiliary cancer subscore (HCS). A minimally important difference from pre-CRT was defined as ≥ 6, 5, and 8 points for FACT-G, HCS, and FACT-Hep, respectively.ResultsOf 157 patients who underwent CRT, 100 completed both pre- and post-CRT surveys and were included in the primary analysis. Median age at diagnosis was 65 years (range, 23-90). National Comprehensive Cancer Network resectability status was resectable (3%), borderline resectable (40%), or locally advanced (57%). Folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) (75%) or gemcitabine and nab-paclitaxel (42%) were given for a median of 6 cycles (range, 0-42) before CRT. Radiation therapy techniques included 3-dimensional conformal (22%), intensity modulated photon (55%), and intensity modulated proton (23%) radiation therapy to a median dose of 50 Gy (range, 36-62.5). Concurrent chemotherapy was most commonly capecitabine (82%). Sixty-three patients (63%) had surgery after CRT. The mean decline in FACT-G, HCS subscale, and FACT-Hep from pre- to post-CRT was 3.5 (standard deviation [SD], 13.7), 1.7 (SD 7.8), and 5.2 (SD 19.4), respectively. Each of these changes were statistically significant, but did not meet the minimally important difference threshold. Pancreatic head tumor location was associated with decline in FACT-Hep. Nausea was the toxicity with the greatest increase from pre- to post-CRT by both physician-assessment and patient-reported QOL.ConclusionsFor patients with intact pancreatic adenocarcinoma, modern CRT is well tolerated with minimal decline in QOL during treatment. 相似文献
154.
Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers
下载免费PDF全文
![点击此处可从《Clinical endocrinology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
155.
156.
157.
158.
Vinke Jeroen Kaper Hans J. Vissink Arjan Sharma Prashant K. 《Clinical oral investigations》2020,24(11):4019-4030
Clinical Oral Investigations - The aims of this study are to assess different saliva substitutes for their efficacy to lubricate the oral cavity, and to relate this oral lubrication to the ability... 相似文献
159.
160.
J. Savige L. Amos Frank Ierino H. G. Mack R. C. Andrew Symons P. Hughes 《Ophthalmic genetics》2016,37(4):369-376
Background: Dense deposit disease and atypical hemolytic uremic syndrome are often caused by Complement Factor H (CFH) mutations. This study describes the retinal abnormalities in dense deposit disease and, for the first time, atypical haemolytic uremic syndrome. It also reviews our understanding of drusen pathogenesis and their relevance for glomerular disease. Methods: Six individuals with dense deposit disease and one with atypical haemolytic uremic syndrome were studied from 2 to 40 years after presentation. Five had renal transplants. All four who had genetic testing had CFH mutations. Individuals underwent ophthalmological review and retinal photography, and in some cases, optical coherence tomography, and further tests of retinal function. Results: All subjects with dense deposit disease had impaired night vision and retinal drusen or whitish-yellow deposits. Retinal atrophy, pigmentation, and hemorrhage were common. In late disease, peripheral vision was restricted, central vision was distorted, and there were scotoma from sub-retinal choroidal neovascular membranes and atypical serous retinopathy. Drusen were present but less prominent in the young person with atypical uremic syndrome due to a heterozygous CFH mutation. Conclusions: Drusen are common in forms of C3 glomerulopathy caused by compound heterozygous or heterozygous CFH mutations. They are useful diagnostically but also impair vision. Drusen have an identical composition to glomerular deposits. They are also identical to the drusen of age-related macular degeneration, and may respond to the same treatments. Individuals with a C3 glomerulopathy should be assessed ophthalmologically at diagnosis, and monitored regularly for vision-threatening complications. 相似文献